立体定向放射治疗早期非小细胞肺癌的研究进展

Research advances for Stereotactic body radiation therapy in early stage Non-small cell lung cancer

立体定向放射治疗(SBRT)已成为医学上不能手术的早期非小细胞肺癌(NSCLC)的标准治疗方式,可以提供不亚于手术的局部肿瘤控制效果。对于可手术的早期NSCLC患者而言,SBRT的疗效与手术相同甚至更优。随着Ⅱ期临床试验的推进,对SBRT的放射生物学特点、治疗技术及相关方法、正常器官/组织的剂量限值、影响疗效的主要因素、SBRT诱导的免疫效应及远隔效应等方面的认识不断深入,这为SBRT的其临床应用提供了可靠的依据。本文综述了SBRT治疗NSCLC在上述方面的最新研究进展。

Stereotactic radiotherapy （SBRT） has become the standard treatment for medically inoperable early non-small cell lung cancer （NSCLC）, providing local tumor control effects comparable to surgery. For operable patients with early-stage NSCLC, the efficacy of SBRT is the same or even better than surgery. With the advancement of Phase Ⅱclinical trials, the understanding of the radiobiological characteristics of SBRT, treatment techniques and related methods, dose limits for normal organs/tissues, major factors affecting efficacy, SBRT-induced immune effects, and distant effects and other aspects is deeper, these provide a reliable basis for the clinical application of SBRT. This article reviews the recent advances in SBRT for NSCLC in these areas.